US 12,291,512 B2
Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor
Giles Albert Brown, Cambridge (GB); and Benjamin Gerald Tehan, Cambridge (GB)
Assigned to Nxera Pharma UK Limited, Cambridge (GB)
Filed by Nxera Pharma UK Limited, Cambridge (GB)
Filed on Dec. 15, 2021, as Appl. No. 17/551,976.
Application 17/551,976 is a continuation of application No. 15/772,785, granted, now 11,208,396, previously published as PCT/GB2016/053396, filed on Nov. 2, 2016.
Claims priority of application No. 1519352 (GB), filed on Nov. 2, 2015.
Prior Publication US 2022/0298133 A1, Sep. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/04 (2006.01); A61P 25/00 (2006.01); A61P 25/04 (2006.01); A61P 25/18 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 43/00 (2006.01)
CPC C07D 401/04 (2013.01) [A61P 25/00 (2018.01); A61P 25/04 (2018.01); A61P 25/28 (2018.01); A61P 25/30 (2018.01); A61P 43/00 (2018.01); A61P 25/18 (2018.01)] 9 Claims
 
1. A compound of formula (1):

OG Complex Work Unit Chemistry
or a salt thereof, wherein:
p is 0;
q is 0;
Y is O;
X1 and X2 are saturated hydrocarbon groups which together contain a total of four to nine carbon atoms and which link together such that the moiety:

OG Complex Work Unit Chemistry
forms a mono or bicyclic ring system;
R1 is selected from methyl, ethyl, propyl, and isopropyl
R2 is selected from cyano, methyl, ethyl, propyl, isopropyl, butyl, and isobutyl;
R3 is selected from hydrogen, fluorine, and methoxy;
R4 is selected from hydrogen, methyl, ethyl, ethynyl, and 1-propynyl;
R5 is fluorine; and
R6 is fluorine.